Skip to Content
Close Icon

COVID-19 Vaccine

COVID-19 BIVALENT VACCINE

On August 31st, 2022 the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.

On September 1st, 2022 the Advisory Committee on Immunization Practices (ACIP) supported the use of the bivalent booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines—targeting the BA.4/BA.5 Omicron subvariants as well as the original variant.

ACIP’s recommendations, following the U.S. Food and Drug Administration’s (FDA) authorization on Wednesday, will allow individuals 12 years and older to receive a booster dose of Pfizer’s bivalent vaccine and anyone 18 years and older to receive a booster dose of Moderna’s bivalent vaccine at least two months after completing their primary vaccine series or their most recent booster.

The bivalent booster recommendation replaces previous booster recommendations with a monovalent booster dose for people ages 12 years and older.The bivalent vaccines, which we will also refer to as “updated boosters,” contain two messenger RNA (mRNA) components of SARS-CoV-2 virus, one of the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2. 

The updated COVID-19 vaccine boosters are designed to give you broad protection against COVID-19, including better protection against the Omicron variant.

The Moderna COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 18 years of age and older.

The Pfizer-BioNTech COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 12 years of age and older. 

What you need to know:

  • The authorized bivalent COVID-19 vaccines, or updated boosters, include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA component in common between the omicron variant BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the omicron variant. 
  • The BA.4 and BA.5 lineages of the omicron variant are currently causing most cases of COVID-19 in the U.S. and are predicted to circulate this fall and winter. In June, the agency’s Vaccines and Related Biological Products Advisory Committee voted overwhelmingly to include an omicron component in COVID-19 booster vaccines.
  • For each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, including extensive safety and effectiveness data for each of the monovalent mRNA COVID-19 vaccines, safety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA from omicron variant BA.1 lineage that is similar to each of the vaccines being authorized, and nonclinical data obtained using a bivalent COVID-19 vaccine that contained mRNA of the original strain and mRNA in common between the BA.4 and BA.5 lineages of the omicron variant.
  • Based on the data supporting each of these authorizations, the bivalent COVID-19 vaccines are expected to provide increased protection against the currently circulating omicron variant. Individuals who receive a bivalent COVID-19 vaccine may experience side effects commonly reported by individuals who receive authorized or approved monovalent mRNA COVID-19 vaccines.
  • With today’s authorization, the monovalent mRNA COVID-19 vaccines are not authorized as booster doses for individuals 12 years of age and older.
  • The agency will work quickly to evaluate future data and submissions to support authorization of bivalent COVID-19 boosters for additional age groups as we receive them.

Who is eligible to receive a single booster dose and when:

  • Individuals 18 years of age and older are eligible for a single booster dose of the Moderna COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. 
  • Individuals 12 years of age and older are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.

The Moderna COVID-19 Vaccine, Bivalent is authorized for use as single booster dose in individuals 18 years of age and older.

For additional information on the Moderna COVID-19 Vaccine, Bivalent, visit https://www.fda.gov/media/144638/download.

The Pfizer BioNTech COVID-19 Vaccine, Bivalent is authorized for use as a single booster dose in individuals 12 years of age and older.

For additional information on the Pfizer BioNTech COVID-19 Vaccine, Bivalent, visit https://www.fda.gov/media/153716/download.

Am I eligible for an updated (bivalent) COVID-19 vaccine booster?

Eligibility for a booster depends on:

  • Your age
  • When you finished primary vaccination
  • When received your most recent booster dose of a monovalent COVID-19 vaccine

If eligible, consider getting a bivalent COVID-19 vaccine booster.

A single booster dose with an updated bivalent COVID-19 vaccine is designed to provide broad protection against COVID-19 and better protection against COVID-19 caused by the currently circulating Omicron variant.

If you are eligible for an updated COVID-19 vaccine booster, the updated booster you receive does not need to be from the same manufacturer that made the vaccine you received for your primary vaccination or previous booster.

 

NOVAVAX COVID-19 VACCINE 

On Tuesday July 19th, 2022 CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that Novavax’s COVID-19 vaccine be used as another primary series option for adults ages 18 years and older. Novavax is administered as a two dose primary series. Each dose is 0.5 mL administered intramusculary and spaced 3 to 8 weeks apart. Novavax’s COVID-19 vaccine is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adults. Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.

Protein subunit vaccines package harmless proteins of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future. Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza, shingles, meningococcal B and whooping cough (acellular pertussis).

Neergaard Pharmacy is now offering COVID-19 vaccine for all patients 3 years of age and older ONLY

There are currently ten COVID-19 vaccine formulations available for use in the United States. Neergaard Pharmacy offers all eight vaccine formulations:

  • Moderna, BIVALENT BOOSTER - booster for ages 18 years and older
  • Moderna - for ages 12 years and older
  • Moderna for ages 6 years to 11 years
  • Moderna - for ages 3 years to 5 years 
  • Pfizer, BIVALENT BOOSTER - booster for ages 12 years and older
  • Pfizer - for ages 12 years and older
  • Pfizer -  for ages 5 years to 11 years
  • Pfizer - for ages 3 years to 4 years
  • Johnson & Johnson Janssen - for ages 18 years and older
  • Novavax - for ages 18 years and older as a primary vaccination series only

 

*THE CENTER FOR DISEASE CONTROL AND PREVENTION (CDC) RECOMMENDS THE ADMINISTRATION OF BOOSTER DOSES FOR ALL ELIGIBLE INDIVIDUALS 5 YEARS OF AGE OR OLDER*

 

HETEROLOGOUS OR "MIX AND MATCH" BOOSTER DOSES

The FDA has also authorized the use of each of the available COVID-19 vaccines as a heterologous (or “mix and match”) booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine. Some people may have a preference for the vaccine type that they originally received and others, may prefer to get a different booster. CDC’s recommendations now allow for this type of mix and match dosing for booster shots.

 

Additional Dose of Pfizer-BioNtech COVID-19 vaccine and the Moderna COVID-19 vaccine in MODERATELY OR SEVERELY IMMUNOCOMPROMISED individuals 

The administration of an additional (i.e. third dose) for certain individuals who are moderately or severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments is approved for both the Pfizer-BioNtech COVID-19 vaccine and the Moderna COVID-19 vaccine. 

The age groups authorized for an additional dose remain the same as those for the primary mRNA COVID-19 dose series (Pfizer: aged ≥12 years or Moderna: aged ≥18 years). 

According to the CDC, an estimated 2.7 percent of adults in the United States are immunocompromised. This proportionally equates to approximately 425,000 adults in NYS. Persons with immunocompromising conditions are more likely to get severely ill from COVID-19, are at a higher risk for prolonged SARS-CoV-2 infection and viral shedding, have increased viral evolution during infection and treatment (hospitalized patients), have low antibody/neutralization titers to SARS-CoV-2 variants, are more likely to transmit SARS-CoV-2 to household contacts, and are more likely to have breakthrough infection. Therefore, certain people who are moderately or severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments, should consult with their healthcare provider to discuss the benefits of an additional dose of an mRNA vaccine, and receive the additional vaccine dose if indicated.

Due to the risk of COVID-19 infection in this population, immunocompromised people should continue to be counseled regarding the potential for a reduced immune response after vaccination and the importance of additional protective measures, regardless of the decision to receive an additional dose of the COVID-19 vaccine. Prevention measures include wearing a mask, staying six feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should be strongly encouraged to be vaccinated against COVID-19.

The additional mRNA COVID-19 vaccine dose is to be administered at least 28 days after the completion of an initial 2 dose primary  mRNA COVID-19 vaccine series in immunocompromised individuals. 

Eligibility for Additional Doses of Pfizer-BioNTech or Moderna COVID-19 Vaccines 

Immunocompromised people who have completed a primary vaccine series (i.e., 2 - dose mRNA vaccine series [Pfizer-BioNTech and Moderna] or single dose of the Janssen vaccine) are considered fully vaccinated ≥2 weeks after completion of the series. However, an additional dose of an mRNA COVID-19 vaccine (at least 28 days following the last dose of the primary COVID-19 vaccine series) should be considered for people with moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments.

These conditions and treatments include but are not limited to:

• Active treatment for solid tumor and hematologic malignancies

• Receipt of solid-organ transplant and taking immunosuppressive therapy

• Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)

• Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)

• Advanced or untreated HIV infection

• Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

The guidance above for an additional dose after an initial primary series is different than a “booster dose”. A “booster dose” is defined as an additional dose of vaccine administered when the initial sufficient immune response to a primary vaccine series is likely to have waned over time. 

Due to the risk of COVID-19 infection in this population, immunocompromised people should continue to be counseled regarding the potential for a reduced immune response after vaccination and the importance of additional protective measures, regardless of the decision to receive an additional dose of the COVID-19 vaccine. Prevention measures include wearing a mask, staying six feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should be strongly encouraged to be vaccinated against COVID-19.

 

Common COVID-19 Vaccine Questions

Side effects confirm the vaccine is working with your immune system

►Side effects may include pain at the injection site, tiredness, headache, muscle and joint pain or chills and fever

►Remember the vaccine does not contain the virus, so it cannot give you COVID-19

Why get the COVID-19 vaccine at Neergaard Pharmacy?

►We have years of experience safely administering vaccines, such as those for flu, shingles and pneumonia

►We offer easy, online scheduling for your COVID-19 vaccine 

►We have been a neighborhood pharmacy in Park Slope, Brooklyn for over 100 years

Who will be administering the COVID-19 Vaccine?

A Neergaard Pharmacist will be administering the COVID-19 vaccine.

What processes are in place to ensure timely and appropriate second dose administration?

All first and second doses of the COVID-19 vaccine will require an appointment. The second COVID-19 dose appointment will be scheduled after you receive your first dose by the vaccinating pharmacist. It is critical that you keep this appointment and complete the two dose series of the vaccine. Upon receiving your first dose, you will be provided with a mandated vaccine card with all relevant vaccination information. Neergaard Pharmacy has a detailed tracking system to make sure we know who received the COVID-19 vaccine and that they get the second dose on schedule. Detailed reporting of all vaccinations will be shared with all state and local public health authorities. 

How will vaccines be handled, distributed and tracked?

Neergaard Pharmacy has put into place essential logisitics, such as ensuring we have appropriate freezer capacity, to ensure that we can handle, distribute, store and track vaccine inventory. 

Will I be charged for the COVID-19 vaccine?

No, patients will not be charged for the vaccine or vaccine administration. The government will pay for the cost of the vaccine, and the healthcare provider who administers the vaccine will be reimbursed by the patient's insurance. 

Do I need an appointment to receive the COVID-19 vaccine?

Yes, an appointment is required to receive the COVID-19 vaccine at Neergaard Pharmacy. If you are unable to schedule an appointment online, please stop by one of our locations and we will assist you. 

What should I bring with me to my COVID-19 vaccine appointment?

►Your CDC vaccination card 

►A valid form of identification

►Your insurance information if you are insured

How is Neergaard Pharmacy prepared to treat potential allergic reactions to the COVID-19 vaccine?

Pharmacist immunizers are trained in the safe administration of COVID-19 vaccines authorized for use by the FDA, including identifying and treating allergic reactions. The vaccination procedure includes a patient screening checklist to assess the risk of reaction. All patients are monitored for 15 minutes after administration of the vaccine or longer for patients with a history of severe allergic reactions. Pharmacists at Neergaard Pharmacy are equipped with appropriate equipment and medications, such as epinephrine and antihistamines, to assess and treat adverse reactions. 

Which COVID-19 Vaccine will be available at Neergaard Pharmacy?

You will receive either the Pfizer-BioNTech COVID-19 vaccine, the Moderna COVID-19 vaccine, the Johnson & Johnson Janssen COVID-19 vaccine or the Novavax COVID-19 vaccine. 

What is the dosing schedule for the Pfizer-BioNTech COVID-19 vaccine?

The Pfizer-BioNTech COVID-19 vaccine is administered as a 2-dose series of 0.3mL each dose, 21 days apart, into the muscle. The Pfizer-BioNTech booster dose is a single dose of 0.3mL administered 5 months or more after the completion of the initial vaccination series. 

What is the dosing schedule for the Pfizer-BioNTech PEDIATRIC COVID-19 vaccine?

The Pfizer-BioNTech COVID-19 vaccine is administered as a 2-dose series of 0.2mL each dose, 21 days apart, into the muscle. 

What is the dosing schedule for the Moderna COVID-19 vaccine?

The Moderna COVID-19 vaccine is administered as a 2-dose series of 0.5 mL each dose, 28 days apart, into the muscle. The Moderna booster dose is a single dose of 0.25mL administered 5 months or more after the completion of the initial vaccination series. 

What is the dosing schedule for the Johnson & Johnson Janssen COVID-19 vaccine?

The Johnson & Johnson Janssen COVID-19 vaccine is administered as a single one time dose of 0.5 mL, into the muscle. The Johnson & Johnson Janssen booster dose is a single dose of 0.5 mL administered 2 months or more after the completion of the primary vaccination.

What is the dosing schedule for the Novavax COVID-19 vaccine?

The Novavax COVID-19 vaccine is administered as 2-dose primary series of 0.5 mL each dose, 3-8 weeks apart, into the muscle. 

What groups are eligible for COVID-19 vaccination at Neergaard Pharmacy?

ALL individuals age 3 and older are eligible to be vaccinated. 

According to the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, minors 3 years of age and older are authorized to receive such vaccine. HOWEVER, MINORS AGE 5 to 17 are NOT authorized to receive the Johnson & Johnson Janssen or Moderna vaccine. 

A minor is defined as an individual under the age of 18. Minors need parental or gaurdian consent to receive a COVID-19 vaccine, except in rare instance where the minor is part of a group to whom the law gives the right to consent to their own care (e.g. married minors, minors who are parents or pregnant, and minors in the military). 

In general, it is strongly encouraged that a parent or legal gaurdian accompany a minor age 5 to 17 to provide in person consent for vaccination at each dose. 

Where can I find more information on the Johnson & Johnson Janssen COVID-19 vaccine?

Visit  Janssen COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov) for more information on the Johnson & Johnson Janssen COVID-19 vaccine. 

Where can I find more information on the Pfizer-BioNTech COVID-19 vaccine?

Visit Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov) for more information on the Pfizer-BioNTech COVID-19 vaccine. 

Where can I find more information on the Pfizer-BioNTech PEDIATRIC (5-11 years old) COVID-19 vaccine?

Visit https://www.fda.gov/media/153717/download for more information on the Pfizer-BioNTech PEDIATRIC (5-11 years old) COVID-19 vaccine. 

Where can I find more information on the Pfizer-BioNTech PEDIATRIC (3-5 years old) COVID-19 vaccine?

VIsit https://www.fda.gov/media/159313/download for more information on rhe Pfizer-BioNTech PEDIATRIC (3-5 years old) COVID-19 vaccine. 

Where can I find more information on the Moderna COVID-19 vaccine?

Visit Moderna COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers (fda.gov)

Where can I find more information on the Moderna PEDIATRIC (3-5 years old) COVID-19 vaccine?

Visit https://www.fda.gov/media/159307/download

Where can I find more information on the Moderna PEDIATRIC (6-11 years old) COVID-19 vaccine?

Visit https://www.fda.gov/media/159310/download

Where can I find more information on the NOVAVAX COVID-19 vaccine?

Visit https://www.fda.gov/media/159898/download

 

What is V-safe?

V-safe is a smartphone based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. 

Visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html for more information on v-safe.

Will both Neergaard locations offer the COVID-19 vaccine?

Yes. You may schedule an appointment to receive the COVID-19 vaccine at both Neergaard 5th Avenue located at 454 5th Avenue and Neergaard 7th Avenue located at 120 7th Avenue.  

How do I schedule an appointment for the COVID-19 Vaccine at Neergaard Pharmacy?

You can schedule an appointment at either Neergaard location by clicking the "Schedule a Vaccine Appointment" button below and selecting the location you would like to receive the vaccine.  

 

5th Avenue Vaccine Appointment

7th Avenue Vaccine Appointment

 

 

 

 

 

Aa Aa Aa